Loading...
•
Mar 31, 2020
Black Diamond Therapeutics Q1 2020 Earnings Report
Reported financial results for the first quarter ended March 31, 2020, and provided a corporate update.
Key Takeaways
Black Diamond Therapeutics reported $357.2 million in cash and cash equivalents as of March 31, 2020. The company completed its initial public offering in February 2020, raising $231.3 million in gross proceeds. They also continued to enroll and dose patients in the Phase 1/2 clinical trial of BDTX-189.
Cash and cash equivalents totaled $357.2 million as of March 31, 2020, expected to fund operations into 2023.
Completed initial public offering in February 2020, raising $231.3 million in gross proceeds.
Continued enrollment and dosing in Phase 1/2 clinical trial of BDTX-189, initiated in December 2019.
Phase 1 portion of the BDTX-189 trial is expected to be completed by the first half of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...